AU602509B2
(en)
*
|
1986-03-13 |
1990-10-18 |
Trustees Of Columbia University In The City Of New York, The |
Use of A,B and C prostaglandins and derivatives therof to treat ocular hypertension and glaucoma
|
US4883819A
(en)
*
|
1986-07-31 |
1989-11-28 |
The Trustees Of Columbia University In The City Of New York |
Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
|
EP0242580B1
(de)
*
|
1986-03-13 |
1993-04-28 |
The Trustees Of Columbia University In The City Of New York |
Verwendung von A-, B- und C-Prostaglandinen und deren Derivaten zur Behandlung von Augen-Hypertension und Glaukom
|
US4824857A
(en)
*
|
1986-05-16 |
1989-04-25 |
Yasumasa Goh |
Use of prostaglandin D2 -active substances
|
US4822819A
(en)
*
|
1986-11-07 |
1989-04-18 |
Alcon Laboratories, Inc. |
Use of trimoprostil and derivatives in glaucoma therapy
|
US4822820A
(en)
*
|
1986-11-24 |
1989-04-18 |
Alcon Laboratories, Inc. |
Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
|
ZA88963B
(en)
*
|
1987-02-27 |
1989-11-29 |
Allergan Inc |
Prostaglandins useful for lowering intraocular pressure
|
ES2042625T5
(es)
*
|
1987-04-03 |
2000-07-16 |
Univ Columbia |
Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
|
US4952581A
(en)
*
|
1987-04-03 |
1990-08-28 |
The Trustees Of Columbia University In The City Of New York |
Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
|
GB8710780D0
(en)
*
|
1987-05-07 |
1987-06-10 |
Scras |
Opthalmological application of eicosapentaenoic acid
|
US5236907A
(en)
*
|
1988-10-01 |
1993-08-17 |
R-Tech Ueno Ltd. |
Ocular hypotensive agents
|
US6420422B1
(en)
|
1987-09-18 |
2002-07-16 |
Sucampo Pharmaceuticals, Inc. |
Ocular hypotensive agents
|
US5212200A
(en)
*
|
1987-09-18 |
1993-05-18 |
R-Tech Ueno, Ltd. |
Ocular hypotensive agents
|
ES2052735T3
(es)
*
|
1987-09-18 |
1994-07-16 |
R Tech Ueno Ltd |
Un metodo para producir un agente hipotensor ocular.
|
US5166178B1
(en)
*
|
1987-09-18 |
1998-07-21 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
US5151444B1
(en)
*
|
1987-09-18 |
1999-07-06 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
EP0310322A3
(de)
*
|
1987-09-30 |
1990-10-10 |
Allergan, Inc |
Verwendung von Thromboxan B2 zur Pupillenverengung und zum Senken des Augeninnendrucks
|
SE8703854D0
(sv)
*
|
1987-10-07 |
1987-10-07 |
Pharmacia Ab |
Prostaglandinderivat for behandling av glaukom eller okuler hypertension
|
US5565492A
(en)
*
|
1988-07-18 |
1996-10-15 |
Alcon Laboratories, Inc. |
Prostaglandin combinations in glaucoma therapy
|
ES2213504T1
(es)
*
|
1988-09-06 |
2004-09-01 |
Pfizer Health Ab |
Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
|
US5321128A
(en)
*
|
1988-09-06 |
1994-06-14 |
Kabi Pharmacia Ab |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5296504A
(en)
*
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US6187813B1
(en)
*
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
EP1300149A3
(de)
*
|
1988-09-06 |
2003-05-14 |
Pharmacia Aktiebolag |
Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
|
EP0580268B1
(de)
*
|
1988-10-01 |
1998-01-14 |
R-Tech Ueno Ltd. |
Oculare hypotensive Mittel
|
US5194429A
(en)
*
|
1988-10-01 |
1993-03-16 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Ocular hypotensive agents
|
US5271939A
(en)
*
|
1988-10-03 |
1993-12-21 |
Alcon Laboratories, Inc. |
Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
|
US5360611A
(en)
*
|
1988-10-03 |
1994-11-01 |
Alcon Laboratories, Inc. |
Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
|
US4927846A
(en)
*
|
1988-11-23 |
1990-05-22 |
Allergan, Inc. |
Intraocular pressure reducing 1,11-lactone prostaglandins
|
US5114971A
(en)
*
|
1989-05-15 |
1992-05-19 |
Kabi Pharmacia Ab |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5034413A
(en)
*
|
1989-07-27 |
1991-07-23 |
Allergan, Inc. |
Intraocular pressure reducing 9,11-diacyl prostaglandins
|
CA2020254A1
(en)
*
|
1989-07-27 |
1991-01-28 |
Ming F. Chan |
Intraocular pressure reducing 9, 15-diacyl prostaglandins
|
US4994274A
(en)
*
|
1989-07-27 |
1991-02-19 |
Allergan, Inc. |
Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
|
US5028624A
(en)
*
|
1989-07-27 |
1991-07-02 |
Allergan, Inc. |
Intraocular pressure reducing 9,15-diacyl prostaglandins
|
AU635294B2
(en)
*
|
1989-07-27 |
1993-03-18 |
Allergan, Inc. |
Intraocular pressure reducing 9,11-diacyl prostaglandins
|
CA2021316C
(en)
*
|
1989-07-27 |
2000-10-24 |
Ming Fai Chan |
Intraocular pressure reducing 11-acyl prostaglandins
|
EP0471856B1
(de)
*
|
1990-03-08 |
1995-03-22 |
Shionogi & Co., Ltd. |
15-deoxyprostaglandinderivat
|
US5292754A
(en)
*
|
1990-03-08 |
1994-03-08 |
Shionogi & Co., Ltd. |
Treatment for hypertension or glaucoma in eyes
|
US5011856A
(en)
*
|
1990-03-12 |
1991-04-30 |
Allergan, Inc. |
Use of prostaglandin F3 α as an ocular hypotensive agent
|
WO1991014428A1
(en)
*
|
1990-03-19 |
1991-10-03 |
Allergan, Inc. |
USE OF 5-TRANS PROSTAGLANDIN F2α AS AN OCULAR HYPOTENSIVE AGENT
|
DK0458590T3
(da)
*
|
1990-05-22 |
1996-02-05 |
R Tech Ueno Ltd |
Behandling af okulær hypertension med en synergistisk konbination
|
DE69106777T2
(de)
*
|
1990-05-22 |
1995-05-18 |
R Tech Ueno Ltd |
Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
|
US5238961A
(en)
*
|
1990-06-14 |
1993-08-24 |
Allergan, Inc. |
Pgf 1-alcohols and their use as ocular hypotensives
|
US5270049A
(en)
*
|
1990-11-09 |
1993-12-14 |
Allergan, Inc. |
2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
|
US5262437A
(en)
*
|
1990-12-10 |
1993-11-16 |
Allergan, Inc. |
Homo-prostaglandin derivatives as ocular hypotensives
|
US5288754A
(en)
*
|
1992-02-04 |
1994-02-22 |
Allergan, Inc. |
Polar C-1 esters of prostaglandins
|
US5352708A
(en)
*
|
1992-09-21 |
1994-10-04 |
Allergan, Inc. |
Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5834498A
(en)
*
|
1992-09-21 |
1998-11-10 |
Allergan |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5688819A
(en)
*
|
1992-09-21 |
1997-11-18 |
Allergan |
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5468778A
(en)
*
|
1992-09-24 |
1995-11-21 |
Allergan, Inc. |
Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
|
CA2146127C
(en)
*
|
1992-10-13 |
2000-06-13 |
Louis Desantis, Jr. |
Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
|
US5332730A
(en)
*
|
1992-10-16 |
1994-07-26 |
Allergan, Inc. |
Azido derivatives of cyclopentane heptanoic or heptenoic acid
|
US5385945A
(en)
*
|
1992-10-21 |
1995-01-31 |
Allergan, Inc. |
7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
|
US5574066A
(en)
*
|
1992-10-28 |
1996-11-12 |
Allergan |
Intraocular pressure reducing 15-acyl prostaglandins
|
US5328933A
(en)
*
|
1992-10-28 |
1994-07-12 |
Allergan, Inc. |
Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
|
US5312842A
(en)
*
|
1992-10-30 |
1994-05-17 |
Allergan, Inc. |
Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
|
US6124353A
(en)
*
|
1992-11-12 |
2000-09-26 |
Allergan Sales, Inc. |
Method of treating ocular hypertension with 8-epi prostaglandins
|
KR950000664A
(ko)
*
|
1993-06-14 |
1995-01-03 |
우에노 도시오 |
신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르
|
US5510383A
(en)
*
|
1993-08-03 |
1996-04-23 |
Alcon Laboratories, Inc. |
Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
|
US6184250B1
(en)
|
1993-08-03 |
2001-02-06 |
Alcon Laboratories, Inc. |
Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
|
US5387608A
(en)
*
|
1993-08-17 |
1995-02-07 |
Allergan, Inc. |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
|
US5624893A
(en)
*
|
1993-10-14 |
1997-04-29 |
Alcon Laboratories, Inc. |
Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
|
US5476872A
(en)
*
|
1993-10-18 |
1995-12-19 |
Allergan, Inc. |
1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
|
US5486540A
(en)
*
|
1993-10-28 |
1996-01-23 |
Allergan, Inc. |
Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
|
US5416106A
(en)
*
|
1993-12-28 |
1995-05-16 |
Allergan, Inc. |
7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
|
US6462077B1
(en)
*
|
1993-12-28 |
2002-10-08 |
Allergan, Inc. |
Thromboxane ligands without blood clotting side effects
|
US5545665A
(en)
*
|
1993-12-28 |
1996-08-13 |
Allergan |
Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
|
US5741812A
(en)
*
|
1993-12-28 |
1998-04-21 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5650431A
(en)
*
|
1993-12-28 |
1997-07-22 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5462968A
(en)
*
|
1994-01-19 |
1995-10-31 |
Allergan, Inc. |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
US5516796A
(en)
*
|
1994-03-24 |
1996-05-14 |
Kabi Pharmacia Ab |
Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
US5767153A
(en)
*
|
1995-06-07 |
1998-06-16 |
Insite Vision Incorporated |
Sustained release emulsions
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US5698598A
(en)
*
|
1995-08-04 |
1997-12-16 |
Allergan |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
US5700835A
(en)
*
|
1995-12-22 |
1997-12-23 |
Alcon Laboratories, Inc. |
3-Oxa-D-prostaglandins for lowering IOP
|
AU7680096A
(en)
*
|
1995-12-22 |
1997-07-17 |
Alcon Laboratories, Inc. |
Combinations of dp and fp type prostaglandins for lowering iop
|
US5866602A
(en)
*
|
1995-12-22 |
1999-02-02 |
Alcon Laboratories, Inc. |
Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
|
US5814660A
(en)
*
|
1995-12-22 |
1998-09-29 |
Alcon Laboratories, Inc. |
9-oxa prostaglandin analogs as ocular hypotensives
|
US5658897A
(en)
*
|
1996-04-08 |
1997-08-19 |
Allergan |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
|
US5735275A
(en)
*
|
1996-06-13 |
1998-04-07 |
Ballou; Jon |
Tonometer utilizing hydraulic pressure
|
DE69705421T2
(de)
|
1996-11-12 |
2002-05-16 |
Alcon Lab Inc |
15-fluoro-prostaglandine als augendrucksenkende mittel
|
CA2269853A1
(en)
|
1996-11-12 |
1998-05-22 |
Paul W. Zinke |
Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives
|
US6680339B2
(en)
|
1996-11-12 |
2004-01-20 |
Alcon Manufacturing, Ltd. |
15-fluoro prostaglandins as ocular hypotensives
|
WO1998033497A1
(en)
|
1997-02-04 |
1998-08-06 |
Johnstone Murray A |
Method of enhancing hair growth
|
US6037368A
(en)
*
|
1997-05-09 |
2000-03-14 |
Mount Sinai School Of Medicine |
8-iso- prostaglandins for glaucoma therapy
|
EP0998277A1
(de)
*
|
1997-05-30 |
2000-05-10 |
Merck & Co., Inc. (a New Jersey corp.) |
Ophthalmische zusammensetzungen zur behandlung des glaukom
|
US5877211A
(en)
*
|
1997-11-21 |
1999-03-02 |
Allergan |
EP2 receptor agonists as neuroprotective agents for the eye
|
US6232344B1
(en)
|
1997-12-22 |
2001-05-15 |
Alcon Laboratories, Inc. |
13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
|
US6156785A
(en)
*
|
1998-01-23 |
2000-12-05 |
Merck Sharp & Dohme B.V. |
Method for increasing oxygen tension in the optic nerve and retina
|
EP1000619A3
(de)
|
1998-06-23 |
2002-07-24 |
Pfizer Products Inc. |
Verfahren zur Behandlung von Glaukoma
|
CA2337399A1
(en)
*
|
1998-07-21 |
2000-02-03 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US6417228B1
(en)
|
1998-11-02 |
2002-07-09 |
Alcon Manufacturing, Ltd.. |
13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
|
US6096783A
(en)
*
|
1998-12-15 |
2000-08-01 |
Alcon Laboratories, Inc. |
Cyclobutane prostaglandin analogues as ocular hypotensive agents
|
US6211226B1
(en)
|
1998-12-17 |
2001-04-03 |
Alcon Laboratories, Inc. |
11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
|
MXPA01008955A
(es)
|
1999-03-05 |
2002-04-24 |
Procter & Gamble |
Analogos de prostaglandinas selectivas de fp no saturadas de c16.
|
AU771130B2
(en)
*
|
2000-01-18 |
2004-03-11 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US6548535B2
(en)
*
|
2000-01-18 |
2003-04-15 |
Merck & Co., Inc. |
Method for treating ocular hypertension
|
AU2001233286B2
(en)
*
|
2000-02-01 |
2006-04-06 |
Cayman Chemical Company, Incorporated |
Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
|
US20020013294A1
(en)
|
2000-03-31 |
2002-01-31 |
Delong Mitchell Anthony |
Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
|
US20020172693A1
(en)
|
2000-03-31 |
2002-11-21 |
Delong Michell Anthony |
Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
|
US20020037914A1
(en)
*
|
2000-03-31 |
2002-03-28 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
AU2001217709B2
(en)
*
|
2000-11-16 |
2005-10-13 |
Alcon Manufacturing, Ltd. |
Combination therapy for lowering and controlling intraocular pressure
|
US6699493B2
(en)
|
2000-11-29 |
2004-03-02 |
Oculex Pharmaceuticals, Inc. |
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
|
BR0209063A
(pt)
*
|
2001-04-19 |
2004-08-10 |
Teika Pharmaceutical Co Ltd |
Medicamentos e kits de uso medicinal
|
GB0112699D0
(en)
|
2001-05-24 |
2001-07-18 |
Resolution Chemicals Ltd |
Process for the preparation of prostglandins and analogues thereof
|
TWI298257B
(en)
|
2001-05-31 |
2008-07-01 |
Allergan Inc |
Hypotensive lipid and timolol compositions and methods of using same
|
US20040254230A1
(en)
*
|
2001-12-03 |
2004-12-16 |
Ogidigben Miller J. |
Method for treating ocular hypertension
|
TW200305424A
(en)
|
2002-01-29 |
2003-11-01 |
Santen Pharmaceutical Co Ltd |
Glaucoma-treating agent comprising bunazosin and prostaglandin
|
US8758733B2
(en)
|
2002-02-04 |
2014-06-24 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US7351404B2
(en)
|
2002-02-04 |
2008-04-01 |
Allergan, Inc. |
Method of enhancing hair growth
|
US9216183B2
(en)
|
2002-02-04 |
2015-12-22 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US20050124595A1
(en)
*
|
2002-03-15 |
2005-06-09 |
Goetz Michael A. |
Compositions and methods for treating glaucoma and ocular hypertension
|
JP2005534653A
(ja)
*
|
2002-06-06 |
2005-11-17 |
メルク フロスト カナダ アンド カンパニー |
眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
|
CA2488802A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
CA2488884A1
(en)
*
|
2002-06-17 |
2003-12-24 |
Merck & Co., Inc. |
Novel maxi-k channel blockers, methods of use and process for making the same
|
US7294646B2
(en)
*
|
2002-06-17 |
2007-11-13 |
Merck & Co. Inc. |
Maxi-k channel blockers, methods of use and process for making the same
|
JP2005532361A
(ja)
*
|
2002-06-17 |
2005-10-27 |
メルク エンド カムパニー インコーポレーテッド |
高眼圧症の治療用の眼科用組成物
|
US6864282B2
(en)
|
2002-08-05 |
2005-03-08 |
Allergan, Inc. |
9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
|
US7109223B2
(en)
*
|
2002-08-28 |
2006-09-19 |
Merck & Co. Inc. |
Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
|
US20050245509A1
(en)
|
2002-08-29 |
2005-11-03 |
Santen Pharmacecutical Co., Ltd. |
Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
|
JP2006505572A
(ja)
*
|
2002-10-25 |
2006-02-16 |
メルク フロスト カナダ アンド カンパニー |
Ep4受容体アゴニストとしての2−ピロリドン
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
US20040216749A1
(en)
*
|
2003-01-23 |
2004-11-04 |
Hosheng Tu |
Vasomodulation during glaucoma surgery
|
US6949518B1
(en)
|
2003-06-25 |
2005-09-27 |
Pao-Hsien Chu |
Methods for treating macular degeneration with topiramate
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US7235586B2
(en)
*
|
2003-09-09 |
2007-06-26 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
|
US20050250737A1
(en)
*
|
2003-11-12 |
2005-11-10 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US7186744B2
(en)
*
|
2003-11-13 |
2007-03-06 |
Allergan, Inc. |
Prostamides for the treatment of glaucoma and related diseases
|
GB0329620D0
(en)
*
|
2003-12-22 |
2004-01-28 |
Pharmagene Lab Ltd |
EP2 receptor agonists
|
BRPI0506983A
(pt)
|
2004-01-20 |
2007-07-03 |
Allergan Inc |
composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US20050244469A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20050244472A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
EP2216026B1
(de)
*
|
2004-07-12 |
2016-04-20 |
Allergan, Inc. |
Ophthalmologische Zusammensetzungen und deren Verwendung zur Behandlung von Augenkrankheiten
|
EP1655021B1
(de)
*
|
2004-11-09 |
2008-10-29 |
Novagali Pharma SA |
Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
|
US7851504B2
(en)
*
|
2005-03-16 |
2010-12-14 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
US9241918B2
(en)
|
2005-03-16 |
2016-01-26 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
PT1864666E
(pt)
*
|
2005-03-31 |
2012-09-06 |
Santen Pharmaceutical Co Ltd |
Agente protector para célula neuronal retiniana contendo derivado de prostaglandina f2 alfa como ingrediente activo
|
JPWO2006112313A1
(ja)
*
|
2005-04-13 |
2008-12-11 |
宇部興産株式会社 |
インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
US7666912B2
(en)
*
|
2006-03-23 |
2010-02-23 |
Massachusetts Eye And Ear Infirmary |
Compositions and methods for reducing body fat
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
JP4583500B2
(ja)
*
|
2006-07-28 |
2010-11-17 |
ファイザー・プロダクツ・インク |
Ep2作動薬
|
CN101495452B
(zh)
*
|
2006-07-28 |
2012-04-25 |
辉瑞产品公司 |
Ep2激动剂
|
EP2054409A2
(de)
*
|
2006-08-23 |
2009-05-06 |
Allergan, Inc. |
Therapeutische substituierte thiazolidinone, oxazolidinone und entsprechende verbindungen
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
EP2077104A1
(de)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
|
US20090170944A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Ophthalmic micellar compositions with enhanced stability
|
US20090169629A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Micellar compositions with ophthalmic applications
|
EP2077105A1
(de)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
|
US8623918B2
(en)
|
2008-10-29 |
2014-01-07 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
US8722739B2
(en)
*
|
2008-10-29 |
2014-05-13 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
US20100204335A1
(en)
*
|
2008-12-01 |
2010-08-12 |
Allergan, Inc. |
Kit and composition for eyelash growth
|
US20110293549A1
(en)
|
2009-02-03 |
2011-12-01 |
Athena Cosmetics, Inc. |
Composition, method and kit for enhancing hair
|
EP2228058A1
(de)
|
2009-03-04 |
2010-09-15 |
Novagali Pharma S.A. |
Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
|
US20100247606A1
(en)
*
|
2009-03-25 |
2010-09-30 |
Allergan, Inc. |
Intraocular sustained release drug delivery systems and methods for treating ocular conditions
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
US20150024024A1
(en)
*
|
2009-04-23 |
2015-01-22 |
Neurotech Usa, Inc. |
Cell Lines That Produce Prostaglandin F2 Alpha (PGF2A) And Uses Thereof
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
US9149484B2
(en)
|
2009-11-09 |
2015-10-06 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
KR20170095402A
(ko)
|
2009-11-09 |
2017-08-22 |
알러간, 인코포레이티드 |
모발 성장을 촉진하기 위한 조성물 및 방법
|
EP2389939A1
(de)
|
2010-05-28 |
2011-11-30 |
Novagali Pharma S.A. |
Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
US9061034B2
(en)
|
2010-07-29 |
2015-06-23 |
Allergan, Inc. |
Preservative free bimatoprost and timolol solutions
|
CA2807081C
(en)
|
2010-07-29 |
2018-09-18 |
Allergan, Inc. |
Preservative free bimatoprost and timolol solutions
|
SG187770A1
(en)
|
2010-08-12 |
2013-03-28 |
Univ Nanyang Tech |
A liposomal formulation for ocular drug delivery
|
EP2982373B1
(de)
|
2011-01-19 |
2018-06-13 |
Topokine Therapeutics, Inc. |
Verfahren und zusammensetzungen zur reduzierung von körperfett
|
US8859616B2
(en)
|
2011-01-21 |
2014-10-14 |
Allergan, Inc. |
Compounds and methods for enhancing hair growth
|
TW202239413A
(zh)
|
2011-02-04 |
2022-10-16 |
日商興和股份有限公司 |
眼科用製劑
|
US8426471B1
(en)
|
2011-12-19 |
2013-04-23 |
Topokine Therapeutics, Inc. |
Methods and compositions for reducing body fat and adipocytes
|
MX2015006390A
(es)
|
2012-11-21 |
2015-08-05 |
Topokine Therapeutics Inc |
Metodos y composiciones para incrementar localmente la grasa corporal.
|
CA2901280A1
(en)
|
2013-02-15 |
2014-08-21 |
Allergan, Inc. |
Sustained drug delivery implant
|
NO2753788T3
(de)
|
2013-05-10 |
2018-06-16 |
|
|
US9820993B2
(en)
|
2013-05-15 |
2017-11-21 |
Topokine Therapeutics, Inc. |
Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
|
WO2015200425A1
(en)
|
2014-06-27 |
2015-12-30 |
Topokine Therapeutics, Inc. |
Topical dosage regimen
|
ES2954412T3
(es)
|
2014-10-20 |
2023-11-22 |
Sentiss Pharma Private Ltd |
Solución oftálmica
|